| Market Cap | 235.92M | P/E | - | EPS this Y | 18.90% | Ern Qtrly Grth | - |
| Income | -99.43M | Forward P/E | -1.90 | EPS next Y | -24.80% | 50D Avg Chg | 13.00% |
| Sales | 2.51M | PEG | -0.41 | EPS past 5Y | - | 200D Avg Chg | -34.00% |
| Dividend | N/A | Price/Book | 0.80 | EPS next 5Y | 16.40% | 52W High Chg | -75.00% |
| Recommedations | 1.90 | Quick Ratio | 20.05 | Shares Outstanding | 62.15M | 52W Low Chg | 70.00% |
| Insider Own | 1.39% | ROA | -25.41% | Shares Float | 43.66M | Beta | 2.28 |
| Inst Own | 98.62% | ROE | -39.00% | Shares Shorted/Prior | 7.26M/3.88M | Price | 3.82 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 720,272 | Target Price | 15.78 |
| Oper. Margin | -4,484.38% | Earnings Date | May 13 | Volume | 367,973 | Change | 2.96% |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Cantor Fitzgerald | Overweight | Jul 10, 24 |
| Cantor Fitzgerald | Overweight | May 20, 24 |
| Goldman Sachs | Buy | May 14, 24 |
| HC Wainwright & Co. | Buy | May 14, 24 |
| Oppenheimer | Outperform | May 14, 24 |
| Goldman Sachs | Buy | May 13, 24 |
| RBC Capital | Outperform | Mar 13, 24 |
| HC Wainwright & Co. | Buy | Feb 28, 24 |
| Piper Sandler | Overweight | Feb 28, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | Jan 20 | Buy | 13.00 | 1,923,076 | 24,999,988 | 11,609,704 | 01/24/23 |
| Gould Robert J | Interim President &.. Interim President & CEO | Jan 13 | Sell | 15.00 | 6,766 | 101,490 | 499,864 | 01/13/23 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | Dec 27 | Buy | 5.9941 | 4,089 | 24,510 | 9,505,925 | 12/29/22 |
| Gould Robert J | Director Director | Jun 07 | Option | 7.84 | 71,435 | 560,050 | 578,065 | 06/08/22 |
| Gould Robert J | Director Director | Jun 07 | Sell | 8.09 | 71,435 | 577,909 | 506,630 | 06/08/22 |
| Gould Robert J | Director Director | Jun 02 | Option | 7.84 | 66,622 | 522,316 | 531,012 | 06/06/22 |
| Gould Robert J | Director Director | Jun 02 | Sell | 7.99 | 66,622 | 532,310 | 506,630 | 06/06/22 |
| Gould Robert J | Director Director | Apr 07 | Option | 7.84 | 5,631 | 44,147 | 512,261 | 04/11/22 |
| Gould Robert J | Director Director | Apr 07 | Sell | 24.02 | 5,631 | 135,257 | 506,630 | 04/11/22 |
| Gould Robert J | Director Director | Apr 01 | Option | 7.84 | 94,251 | 738,928 | 559,182 | 04/05/22 |
| Gould Robert J | Director Director | Apr 01 | Sell | 24.1 | 94,251 | 2,271,449 | 506,630 | 04/05/22 |